Developmental Therapeutics Program News Today

Trials because they are being treated in places that are not running trials. We need to move this out in to the community, make those folks eligible. And im on the committee in the lung map trial, and i have really urged that we make sure that we are out there in the community so that anyone who has lung cancer has an opportunity to participate in the research and perhaps, have a more effective therapy. So, i think the Electronic Health records that its a huge different area that we are working ...

And im on the committee in the lung map trial, and i have really urged that we make sure that we are out there in the community so that anyone who has lung cancer has an opportunity to participate in the research and perhaps, have a more effective therapy. So, i think the Electronic Health records that its a huge different area that we are working on and how to do Clinical Trials utilizing the infrastructure that is emerging. Right, thank you very much. Chair, thanks, gentle lady, and now recogn...

The FDA has expanded the approval of Lutathera (lutetium Lu 177 dotatate) to include pediatric patients with SSTR-positive GEP-NETs.

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric and adult patients Gastroenteropancreatic neuroendocrine...

The FDA has approved lutetium Lu 177 dotatate for pediatric patients 12 years of age and older with SSTR–positive GEP-NETs.

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17)...

This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and...

An expert explained the importance of patient choice in treatment decisions for high-risk, resectable melanoma, based on their own treatment goals.

Daniel Spratt, MD, discusses ongoing debate and uncertainties regarding the optimal use of treatment intensification in high-risk prostate cancer.